Subsequent to the return treatment, BTN2A2 antibody on the surface of the droplet inhibited the proliferation of Tregs and MDSCs in the tumor, and CMP within the droplet increased the ability of T cells to infiltrate the tumor microenvironment. The gene discussed is BTN2A2; the disease is neoplasm.